The role of tryptophan 1072 in human PDE3B inhibitor binding

被引：7

作者：

Chung, C

Varnerin, JP

Morin, NR

MacNeil, DJ

Singh, SB

Patel, S

Scapin, G

Van der Ploeg, LHT

Tota, MR

机构：

[1] Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA

[2] Merck Res Labs, Dept Mol Syst, Rahway, NJ 07065 USA

[3] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA

[4] MRL San Diego Neurosci Ctr, San Diego, CA USA

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2003年 / 307卷 / 04期

关键词：

D O I：

10.1016/S0006-291X(03)01299-3

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The catalytic domain of recombinant human PDE3B was expressed in Escherichia coli as inclusion bodies and refolded to form active enzyme. A mutation at tryptophan 1072 in PDE3B disrupts inhibitor binding, but has minimal effect on cAMP hydrolysis. The W1072A mutation caused a 158-fold decrease in affinity for cilostamide, a 740-fold decrease for cGMP, and a 15-fold decrease in affinity for IBMX. The corresponding tyrosine mutation had a smaller effect. However, the K-m of cAMP for the W1072A mutation was only increased by about 7-fold. The data indicate that the inhibitor binding region is not completely coincident with the substrate binding region. The homologous residue in PDE4B is located on helix 16 within 7Angstrom of the predicted bound substrate. A model of PDE3B was constructed based on the X-ray crystal structure of PDE4B. (C) 2003 Elsevier Inc. All rights reserved.

引用

收藏

页码：1045 / 1050

页数：6

相关论文

共 12 条

[1] Molecular docking of competitive phosphodiesterase inhibitors [J].

Dym, O ;

Xenarios, I ;

Ke, HM ;

Colicelli, J .

MOLECULAR PHARMACOLOGY, 2002, 61 (01) :20-25

[2] Expression and Characterization of Deletion Recombinants of Two cGMP-Inhibited Cyclic Nucleotide Phosphodiesterases (PDE-3) [J].

He R. ;

Komas N. ;

Ekholm D. ;

Murata T. ;

Taira M. ;

Hockman S. ;

Degerman E. ;

Manganiello V.C. .

Cell Biochemistry and Biophysics, 1998, 29 (1-2) :89-111

[3] Preparation of aromatic polycarbonate nanoparticles using supercritical carbon dioxide [J].

Lee, JY ;

Song, CH ;

Kim, JI ;

Kim, JH .

JOURNAL OF NANOPARTICLE RESEARCH, 2002, 4 (1-2) :53-59

[4] CLONING AND EXPRESSION OF A HUMAN GLUCAGON RECEPTOR [J].

MACNEIL, DJ ;

OCCI, JL ;

HEY, PJ ;

STRADER, CD ;

GRAZIANO, MP .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 198 (01) :328-334

[5]

PILLAI R, 1994, J BIOL CHEM, V269, P30676

[6] USE OF A YEAST EXPRESSION SYSTEM FOR THE ISOLATION AND ANALYSIS OF DRUG-RESISTANT MUTANTS OF A MAMMALIAN PHOSPHODIESTERASE [J].

PILLAI, R ;

KYTLE, K ;

REYES, A ;

COLICELLI, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) :11970-11974

[7] DISTINCTIVE ANATOMICAL PATTERNS OF GENE-EXPRESSION FOR CGMP-INHIBITED CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES [J].

REINHARDT, RR ;

CHIN, E ;

ZHOU, J ;

TAIRA, M ;

MURATA, T ;

MANGANIELLO, VC ;

BONDY, CA .

JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (04) :1528-1538

[8] Refolding, purification, and characterization of human recombinant PDE4A constructs expressed in Escherichia coli [J].

Richter, W ;

Hermsdorf, T ;

Lilie, H ;

Egerland, U ;

Rudolph, R ;

Kronbach, T ;

Dettmer, D .

PROTEIN EXPRESSION AND PURIFICATION, 2000, 19 (03) :375-383

[9] Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDES) - Two N-terminal, domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum [J].

Shakur, Y ;

Takeda, K ;

Kenan, Y ;

Yu, ZX ;

Rena, G ;

Brandt, D ;

Houslay, MD ;

Degerman, E ;

Ferrans, VJ ;

Manganiello, VC .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (49) :38749-38761

[10] Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity [J].

Xu, RX ;

Hassell, AM ;

Vanderwall, D ;

Lambert, MH ;

Holmes, WD ;

Luther, MA ;

Rocque, WJ ;

Milburn, MV ;

Zhao, YD ;

Ke, HM ;

Nolte, RT .

SCIENCE, 2000, 288 (5472) :1822-1825